For research use only. Not for therapeutic Use.
PC945（Cat No.:I016665）is a novel antifungal compound designed for the treatment of respiratory fungal infections, particularly invasive aspergillosis. This triazole-based antifungal works by inhibiting lanosterol 14α-demethylase, a key enzyme in ergosterol biosynthesis, leading to the disruption of fungal cell membranes. PC945 is formulated for inhalation, allowing direct delivery to the lungs for localized treatment, minimizing systemic exposure and reducing potential side effects. Its targeted approach and broad-spectrum activity against fungal pathogens make it a promising candidate for addressing respiratory fungal infections, especially in immunocompromised patients.
| Catalog Number | I016665 |
| CAS Number | 1931946-73-4 |
| Molecular Formula | C₃₈H₃₇F₃N₆O₃ |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| IUPAC Name | 4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]-3-methylphenyl]piperazin-1-yl]-N-(4-fluorophenyl)benzamide |
| InChI | InChI=1S/C38H37F3N6O3/c1-26-18-33(46-16-14-45(15-17-46)32-9-2-28(3-10-32)37(48)44-31-7-4-29(39)5-8-31)11-13-36(26)49-21-27-20-38(50-22-27,23-47-25-42-24-43-47)34-12-6-30(40)19-35(34)41/h2-13,18-19,24-25,27H,14-17,20-23H2,1H3,(H,44,48)/t27-,38+/m1/s1 |
| InChIKey | OSAMZQJKSCAOHA-CWRQMEKBSA-N |
| SMILES | CC1=C(C=CC(=C1)N2CCN(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)F)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F |
| Reference | [1]. Colley T, et al. In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02280-16.<br>[2]. Colley T, et al. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. Sci Rep. 2019 Jul 1;9(1):9482. |
